GSK
-
GSK gets pneumococcal vaccine contender with $2.1B Affinivax acquisition
Pfizer and Merck have each won FDA approvals in the past year for new pneumococcal vaccines, but GSK aims to top both of them with its $2.1 billion acquisition of Affinivax. That biotech’s Phase 3-ready vaccine candidate addresses more bacterial strains than any pneumococcal vaccines currently available.
-
INVEST Digital Health preview: The role of digital twins in life sciences
INVEST Digital Health kicks off today and runs through September 23. Held in a virtual format due to Covid-19, the healthcare conference brings together innovative investors across the healthcare spectrum, prominent industry players and the most promising digital health startups. Register today!
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Teva’s generic label not skinny enough to protect from $234M damages to GSK
When is a skinny label skinny enough to protect a generic drug from claims of patent infringement? The answer remains up to interpretation after an important, controversial decision from the Federal Circuit.
-
Faced with slowing demand, 23andMe cuts 100 employees
The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.
-
Special Reports, Artificial Intelligence
AI in healthcare has spurred exciting applications and collaboration
Our latest eBook offers examples of how some of the players in healthcare are thinking about AI, seeking to apply it across care coordination, drug development and early detection of disease and how to address some of the challenges the technology poses for adoption and implementation.
-
Artificial Intelligence, BioPharma
AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate
The in vivo molecule was discovered under a two-year-old partnership between the two companies to discovery drugs using artificial intelligence. It will be developed for COPD.
-
More than half of patients willing to use digital therapeutic, study says
The report also found that 56 percent of physicians have brought up the potential for a digital therapy as an option for their patients, and 26 percent have discussed the option after a patient brought it up.
-
GSK-Pfizer deal illustrates risks and rewards of moving up the biopharma value chain
The potential rewards for drugmakers’ investments in pharmaceuticals and vaccines are enormous, but so are the risks, an industry consultant said.
-
Orchard Therapeutics closes $150 million Series C round
The oversubscribed round comes just four months after acquisition of GSK’s gene therapy portfolio.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
What have pharma companies learned from digital health mistakes?
A panel discussion at the Eye for Pharma conference in Philadelphia this week reflected how pharma companies such as GSK and Novartis are improving the way they use technology and lessons they’ve learned as data science becomes a driving force behind their businesses.
-
Owlstone Medical advances breath biopsy applications in COPD clinical trial with GSK
The study will seek to determine whether Owlstone Medical’s breath biospy tool can match the right patient for the right treatment and to assess the treatment effects of a novel drug for COPD.
-
GSK found liable in law partner’s 2010 suicide
A lawsuit was brought by Reed Smith partner Stewart Dolin’s widow, Wendy Dolin, who claimed her husband’s suicide was the result of a paroxetine side effect.
-
Emma Walmsley makes history as Big Pharma’s first female CEO
On Friday, GlaxoSmithKline’s CEO of eight years, Andrew Witty, will formally retire and take a sliver of the proverbial glass ceiling with him. His replacement, Emma Walmsley, will be the first female head of a Big Pharma company.
-
Gilead, GSK, share potential advancements in HIV
Two significant HIV announcements have already dropped at the Conference on Retroviruses and Opportunistic Infections in Seattle this week, courtesy of Gilead, GSK’s ViiV Healthcare and J&J’s Janssen Sciences Ireland.
-
FDA clears Propeller Health sensor for GSK Ellipta inhaler
Propeller and GlaxoSmithKline announced a joint development agreement less than a year ago.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
